AAM Congratulates Dr. Tidmarsh on Appointment as Director of CDER
WASHINGTON (July 21, 2025) — The Association for Accessible Medicines and the Biosimilars Council today congratulates George Francis Tidmarsh, M.D., Ph.D., on his appointment as Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.
“Alongside our Biosimilars Council, AAM and its members welcome George Francis Tidmarsh, M.D., Ph.D., as the FDA’s newest Director of the Center for Drug Evaluation and Research at the FDA,“ said John Murphy III, President and CEO of AAM.“ Improving the health of patients through more timely access to lower-cost generic and biosimilar medicines is essential to the livelihood of America. We look forward to a collaborative partnership with Dr. Tidmarsh and the larger team at CDER to prioritize regulatory efficiency and help ensure the medicines that cost less and make up 90 percent of all prescriptions filled in the U.S. are always available for patients.”
AAM and the Biosimilars Council congratulate Dr. Tidmarsh and stand ready to support CDER’s continued success in advancing public health.
For media inquiries, contact media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
